• En
  • 中文

Home

  • BeiGene

Main navigation

  • About
    • Our Story
    • Leadership Team
    • Focus on Quality
    • Who we are
    • Ethics
  • Science & Pipeline
    • Research & Development
    • Manufacturing
    • Pipeline
      • Zanubrutinib
      • Tislelizumab
      • Pamiparib
      • Lifirafenib
      • Preclinical Candidates
  • Patients
    • Clinical Trials
    • Access to Investigational Medicines
  • BeiGene
  • Partnering
    • Doing Business in China
  • Investors
    • NASDAQ investors
    • HKEX investors
  • Careers
    • Culture & Benefits
    • Job Opportunities
  • Media
  • Contact
  • Search

Investors Overview

  • Stock Information
  • Financial Information
    • SEC Filings
  • News & Events
    • Press Releases
    • Event Calendar
  • Publications
  • Corporate Governance
  • Investor Services
  • FAQ

NASDAQ Investors

SEC Filings

Form 4/A
BEIGENE, LTD. filed this Form 4/A on 02/13/2018
Document Outline
Entire Document (2.6 KB)
Subdocument 1 - 4/A - FORM 4/A -

Investors

  • NASDAQ Investors
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Tax Information
    • Shareholder Meeting
  • News & Events
    • Press Releases
    • Events Calendar
  • Publications
  • Corporate Governance
    • Documents & Charters
  • Management Team
  • Investor Services
    • Information Request
    • E-mail Alerts
    • IR Contact
  • Investor FAQ
Print Page Print Page   E-mail Page E-mail Page   RSS RSS   E-mail Alerts E-mail Alerts   Tearsheet Tearsheet

Site Navigation

  • About
  • Science & Pipeline
  • Patients
  • BeiGene
  • Partnering
  • Investors
  • Careers

© 2018 BeiGene. All Rights Reserved.

  • Media
  • Contact
  • Site Map
  • Terms of Use
  • Privacy Policy